DENVER--(BUSINESS WIRE)--TriSalus Life Sciences (“TriSalus”), a company committed to transforming outcomes for patients with solid tumors, today announced the appointment of Rajesh B. Mistry as Chief Financial Officer. Mr. Mistry joins TriSalus with a wide spectrum of healthcare experience, spanning pharmaceuticals, biotech, medical devices, and healthcare services. His background extends from VC-backed start-ups to publicly traded, multinational corporations where he drove M&A, corporate finance and capital raising efforts.
“We are very pleased to have Raj lead our finance team as we work to execute our cell therapy and immunomodulation asset acquisition strategy and transition the company to deliver a combination of cutting-edge therapies to attack solid tumors,” said Mary T. Szela, President and CEO. “Additionally, his proven strategic, industry and Wall Street expertise further strengthens our leadership team and positions the company for future success and continued growth.”
Raj brings nearly 15 years of experience to TriSalus, most recently serving as head of Corporate Development at Option Care Health, a leading provider of home and alternate site infusion services, where he directed, through execution of acquisitions, the expansion of Option Care Health’s operations into new geographies. Prior to Option Care Health, Raj drove strategic finance, capital raising and M&A efforts at Melinta Therapeutics, a company focused on the discovery, development and commercialization of novel antibiotics. In addition, Raj held various corporate finance and M&A roles of increasing responsibility at Baxter International, and began his career in healthcare investment banking at A.G. Edwards Capital Markets. Raj has a unique set of experience across various sectors of healthcare driving corporate strategy, raising capital, and sourcing and executing partnership opportunities.
Raj received his Bachelor of Science in Finance from Indiana University’s Kelley School of Business.
“I am very excited to join Mary and the TriSalus team in their commitment to transforming the lives of patients suffering from solid tumors. I am looking forward to putting my financial and strategic expertise to use as TriSalus moves forward with its bold treatment strategy,” said Mr. Mistry.
TriSalus is working to improve patient outcomes and redefine the standard of care for treating solid tumors. TriSalus’ tri-pronged approach combines CAR-T and immunomodulation therapies with proprietary, intravascular delivery offering a new reason for hope among those suffering from solid tumors. TriSalus™ Infusion Systems have the potential to deliver diagnostic agents, therapeutics, and immuno-stimulants directly into tumor vasculature powered by its proprietary Pressure-Enabled Drug Delivery™ (PEDD™) approach with SmartValve™ technology to improve the distribution and penetration of therapy in solid tumors. This innovative approach has the potential to allow for the administration of multiple mechanisms that can work together to overcome inherent immune suppression within the solid tumor microenvironment. For more information, please visit www.trisaluslifesci.com.